Supreme Court Narrows Induced Infringement Claims in Hikma v. Amarin

June 9, 2026

The U.S. Supreme Court issued a unanimous decision on June 4, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., tightening the standard for alleging induced patent infringement in the context of generic drug “skinny labels.”

The Court held that Amarin failed to plausibly allege that Hikma took active, affirmative steps to encourage physicians to prescribe its generic icosapent ethyl for Amarin’s patented cardiovascular (CV) indication. The ruling reverses the Federal Circuit and reinstates the district court’s dismissal.

Justice Jackson, writing for the Court, emphasized that inducement under 35 U.S.C. §271(b) requires clear, affirmative conduct — not passive behavior, foreseeable misuse, or statements that merely could be interpreted as encouragement. As the opinion put it, Amarin’s allegations showed “no more than a sheer possibility” of inducement.

Background

Vascepa, Amarin’s icosapent ethyl product, was first approved in 2012 for severe hypertriglyceridemia (SH). In 2019, the FDA approved a second use — reducing cardiovascular risk in statin‑treated patients — and Amarin secured method‑of‑use patents for that CV indication.

Hikma sought approval for a generic version and, after Amarin’s SH patents were invalidated, pursued a § viii skinny label covering only the unpatented SH indication. The FDA approved the skinny label in 2020 and assigned an AB therapeutic‑equivalence rating.

Amarin’s Allegations

Amarin argued that Hikma’s:

• label (which mirrored Vascepa’s except for the carved‑out use),
• patient leaflet,
• website language, and
• press releases describing the product as “generic Vascepa,”

collectively encouraged infringing CV‑use prescriptions.

The Court’s Analysis

The Court rejected that theory on three grounds:

1. Lawful explanations dominate.

Label content was dictated by the statutory “duty of sameness,” and describing a product as a “generic equivalent” is standard industry practice — not inducement.

2. Omissions are not affirmative acts.

Failing to mention the limited indication is not actionable. The Court reiterated that inducement cannot rest on “mere omissions, inactions, or nonfeasance.”

3. Remaining statements were too vague.

Warnings in the patient leaflet, broad therapeutic‑category labels on the website, and sales figures in press releases did not amount to clear encouragement to infringe.

Impact

The decision reinforces a high bar for induced‑infringement claims against generic manufacturers using skinny labels. It also signals the Court’s intent to rein in the Federal Circuit’s recent trend of treating ambiguous or neutral statements as potential inducement.

For pharmaceutical companies navigating ANDA strategies, the ruling provides renewed clarity: compliance with FDA labeling requirements and standard industry communications cannot, without more, support an inducement claim.

Case Overview

The Supreme Court held that Amarin failed to plausibly allege that Hikma took “active steps” to induce infringement of Amarin’s patented cardiovascular (CV) method of using Vascepa. The Court reversed the Federal Circuit and reinstated the district court’s dismissal.

The Court concluded Amarin alleged “no more than a sheer possibility” of inducement.

Background

• Vascepa (icosapent ethyl)
  • 2012: FDA approval for severe hypertriglyceridemia (SH).
  • 2019: FDA approval for reducing cardiovascular risk in statin‑treated patients (CV indication).
  • Amarin holds method‑of‑use patents for the CV indication.
• Hikma’s ANDA Path
  • Filed ANDA in 2016.
  • After Amarin’s SH patents were invalidated, Hikma submitted a § viii statement and sought a skinny label covering only the unpatented SH indication.
  • FDA approved the skinny label in 2020 and assigned an AB rating.

Amarin’s Theory of Inducement

Amarin argued that Hikma’s label, patient leaflet, website, and press releases — taken together — encouraged doctors to prescribe Hikma’s generic for the patented CV use.

Examples include:

• Label retained a clinical‑study reference involving statin users.
• Leaflet warned about side effects in “people who have heart (cardiovascular) disease.”
• Website listed therapeutic category as “hypertriglyceridemia.”
• Press releases called the product “generic Vascepa” and cited Vascepa’s total sales.

Legal Standard Clarified

To plead active inducement under 35 U.S.C. §271(b), a plaintiff must allege:

1. Direct infringement by a third party.
2. Knowledge that the induced acts constitute infringement.
3. Active steps to encourage infringement.

The Court emphasized the third element:

• Inducement requires “affirmative” conduct, not “mere knowledge” or “ordinary acts incident to product distribution.”

The Court expressly rejected the Federal Circuit’s focus on whether a doctor could read the statements as encouragement.

Why Amarin’s Claim Fails

1. Obvious lawful explanations

Many statements were required by law or standard practice:

• The label had to be the same as Vascepa’s except for carved‑out uses.
• Hikma’s label “must be identical to Amarin’s except for the carved‑out use.”
• Calling a product a “generic equivalent” is normal industry behavior.

2. Omissions are not inducement

Failing to mention the limited indication is not an affirmative act.

• Amarin cannot rely on “mere omissions, inactions, or nonfeasance.”

3. Remaining statements are too vague

• Leaflet warnings and disclaimers are not inducement.
• Website’s broad therapeutic category and AB rating do not “stimulate others to commit” infringement.
• Press‑release sales figures require speculative leaps.

Holding

The Supreme Court reverses the Federal Circuit.

Amarin’s complaint does not plausibly allege that Hikma took active, affirmative steps to induce infringement.

This decision breathes new life into skinny labels to avoid infringement provided one avoids active, affirmatives steps to induce infringement.